Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.
Study Type
OBSERVATIONAL
Enrollment
20
No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
UCSD Moores Cancer Center
San Diego, California, United States
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
MD Anderson Cancer Center
Houston, Texas, United States
Overall Survival (OS) post-Infusion
OS defined as the interval between the date of the first NK cell infusion and the date of death due to any cause
Time frame: From the date of study entry until the date of documented death due to any cause, assessed up to 60 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.